ProKidney (PROK) Competitors

$1.66 -0.05 (-2.92%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.02 (+1.08%)

As of 05/15/2026 07:56 PM Eastern

PROK vs. TRVI, GENB, TYRA, AUPH, and PHVS

Should you buy ProKidney stock or one of its competitors? MarketBeat compares ProKidney with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProKidney include Trevi Therapeutics (TRVI), Generate Biomedicines (GENB), Tyra Biosciences (TYRA), Aurinia Pharmaceuticals (AUPH), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does ProKidney compare to Trevi Therapeutics?

ProKidney (NASDAQ:PROK) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Trevi Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-7,725.20%	N/A	-18.83%
Trevi Therapeutics	N/A	-24.53%	-23.37%

Trevi Therapeutics has lower revenue, but higher earnings than ProKidney. Trevi Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$893K	561.23	-$68.99M	-$0.52	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A

ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 345.78%. Trevi Therapeutics has a consensus target price of $22.90, indicating a potential upside of 61.27%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Comparatively, 18.3% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, ProKidney had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 9 mentions for ProKidney and 6 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.89 beat ProKidney's score of -0.02 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trevi Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ProKidney and Trevi Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does ProKidney compare to Generate Biomedicines?

ProKidney (NASDAQ:PROK) and Generate Biomedicines (NASDAQ:GENB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Generate Biomedicines has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-7,725.20%	N/A	-18.83%
Generate Biomedicines	N/A	N/A	N/A

Generate Biomedicines has higher revenue and earnings than ProKidney.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$893K	561.23	-$68.99M	-$0.52	N/A
Generate Biomedicines	$30.30M	67.69	N/A	N/A	N/A

ProKidney currently has a consensus target price of $7.40, indicating a potential upside of 345.78%. Generate Biomedicines has a consensus target price of $25.40, indicating a potential upside of 58.75%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Generate Biomedicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Generate Biomedicines	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

51.6% of ProKidney shares are owned by institutional investors. 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Generate Biomedicines had 3 more articles in the media than ProKidney. MarketBeat recorded 12 mentions for Generate Biomedicines and 9 mentions for ProKidney. ProKidney's average media sentiment score of -0.02 beat Generate Biomedicines' score of -0.15 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Generate Biomedicines	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney and Generate Biomedicines tied by winning 6 of the 12 factors compared between the two stocks.

How does ProKidney compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Tyra Biosciences presently has a consensus target price of $46.50, indicating a potential upside of 25.54%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 345.78%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tyra Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Tyra Biosciences had 1 more articles in the media than ProKidney. MarketBeat recorded 10 mentions for Tyra Biosciences and 9 mentions for ProKidney. Tyra Biosciences' average media sentiment score of 0.08 beat ProKidney's score of -0.02 indicating that Tyra Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tyra Biosciences has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ProKidney has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A
ProKidney	$893K	561.23	-$68.99M	-$0.52	N/A

Tyra Biosciences has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tyra Biosciences	N/A	-46.72%	-43.41%
ProKidney	-7,725.20%	N/A	-18.83%

Summary

ProKidney beats Tyra Biosciences on 9 of the 15 factors compared between the two stocks.

How does ProKidney compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, indicating a potential upside of 12.89%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 345.78%. Given ProKidney's higher probable upside, analysts clearly believe ProKidney is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, ProKidney had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 9 mentions for ProKidney and 5 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.39 beat ProKidney's score of -0.02 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	6.94	$287.20M	$2.17	7.04
ProKidney	$893K	561.23	-$68.99M	-$0.52	N/A

Aurinia Pharmaceuticals has a net margin of 99.97% compared to ProKidney's net margin of -7,725.20%. Aurinia Pharmaceuticals' return on equity of 26.62% beat ProKidney's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
ProKidney	-7,725.20%	N/A	-18.83%

Summary

Aurinia Pharmaceuticals and ProKidney tied by winning 8 of the 16 factors compared between the two stocks.

How does ProKidney compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

ProKidney has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
ProKidney	$893K	561.23	-$68.99M	-$0.52	N/A

Pharvaris has a net margin of 0.00% compared to ProKidney's net margin of -7,725.20%. ProKidney's return on equity of 0.00% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
ProKidney	-7,725.20%	N/A	-18.83%

51.6% of ProKidney shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Pharvaris had 2 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Pharvaris and 9 mentions for ProKidney. Pharvaris' average media sentiment score of 0.50 beat ProKidney's score of -0.02 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharvaris has a beta of -2.34, meaning that its stock price is 334% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 61.78%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 345.78%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

ProKidney beats Pharvaris on 11 of the 16 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$516.28M	$3.04B	$6.43B	$12.48B
Dividend Yield	N/A	1.96%	2.80%	5.25%
P/E Ratio	-3.19	17.11	20.38	25.24
Price / Sales	561.23	303.32	566.19	82.25
Price / Cash	N/A	57.86	43.04	56.04
Price / Book	-0.49	4.33	9.87	6.90
Net Income	-$68.99M	$72.19M	$3.57B	$334.66M
7 Day Performance	-10.75%	-3.06%	0.31%	0.13%
1 Month Performance	-14.87%	-3.05%	-1.27%	1.11%
1 Year Performance	105.80%	36.81%	33.54%	30.62%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.4905 of 5 stars	$1.66 -2.9%	$7.40 +345.8%	+95.4%	$516.28M	$893K	N/A	3	News Coverage Earnings Report Analyst Downgrade
TRVI Trevi Therapeutics	3.7325 of 5 stars	$15.27 +3.5%	$22.90 +50.0%	+129.4%	$2.10B	N/A	N/A	20
GENB Generate Biomedicines	N/A	$16.22 +4.7%	$25.00 +54.1%	N/A	$2.08B	$30.30M	N/A	312	Analyst Forecast Analyst Revision
TYRA Tyra Biosciences	3.065 of 5 stars	$36.18 +3.8%	$46.50 +28.5%	+275.7%	$2.07B	N/A	N/A	20	Earnings Report Analyst Forecast Analyst Revision
AUPH Aurinia Pharmaceuticals	2.823 of 5 stars	$16.03 +0.3%	$17.25 +7.6%	+87.5%	$2.06B	$283.05M	7.39	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. TRVI, GENB, TYRA, AUPH, and PHVS

How does ProKidney compare to Trevi Therapeutics?

Summary

How does ProKidney compare to Generate Biomedicines?

Summary

How does ProKidney compare to Tyra Biosciences?

Summary

How does ProKidney compare to Aurinia Pharmaceuticals?

Summary

How does ProKidney compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. TRVI, GENB, TYRA, AUPH, and PHVS

How does ProKidney compare to Trevi Therapeutics?

Is PROK or TRVI more profitable?

Which has stronger valuation & earnings, PROK or TRVI?

Which has more volatility & risk, PROK or TRVI?

Do analysts recommend PROK or TRVI?

Do insiders & institutionals believe in PROK or TRVI?

Does the media favor PROK or TRVI?

Summary

How does ProKidney compare to Generate Biomedicines?

Is PROK or GENB more profitable?

Which has stronger valuation & earnings, PROK or GENB?

Do analysts recommend PROK or GENB?

Do insiders & institutionals believe in PROK or GENB?

Does the media refer more to PROK or GENB?

Summary

How does ProKidney compare to Tyra Biosciences?

Do analysts rate TYRA or PROK?

Does the media refer more to TYRA or PROK?

Which has more volatility & risk, TYRA or PROK?

Do institutionals & insiders believe in TYRA or PROK?

Which has preferable earnings and valuation, TYRA or PROK?

Is TYRA or PROK more profitable?

Summary

How does ProKidney compare to Aurinia Pharmaceuticals?

Do analysts rate AUPH or PROK?

Does the media refer more to AUPH or PROK?

Which has more volatility & risk, AUPH or PROK?

Do institutionals & insiders believe in AUPH or PROK?

Which has preferable earnings and valuation, AUPH or PROK?

Is AUPH or PROK more profitable?

Summary

How does ProKidney compare to Pharvaris?

Which has better earnings & valuation, PHVS or PROK?

Is PHVS or PROK more profitable?

Do insiders and institutionals believe in PHVS or PROK?

Does the media prefer PHVS or PROK?

Which has more risk & volatility, PHVS or PROK?

Do analysts rate PHVS or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools